InsightfulValue
โ† Home

Takeda Pharmaceutical
Takeda Pharmaceutical

Pharma / Pharmaceuticals, Healthcare


๐Ÿ”ง Tools

โœ… Due Diligence
๐Ÿ“ข Press Releases

Date Press release
2026-03-28 15:00:00 Takedaโ€™s Zasocitinib Delivered Rapid And Durable Skin Clearance In A Convenient Once-daily Pill, Affirming Promise To Reshape Psoriasis Care
Osaka, japan & cambridge, mass.--(business wire)--takedaโ€™s zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care.
2026-03-02 02:00:00 Takeda And Protagonist Announce U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Rusfertide As A Potential First-in-class Therapy For Polycythemia Vera
Osaka, japan & cambridge, mass. & newark, calif.--(business wire)--takeda (tse:4502/nyse:tak) and protagonist therapeutics, inc. (โ€œprotagonistโ€) (nasdaq:ptgx) today announced that the u.s. food and drug administration (fda) accepted the new drug application (nda) and granted priority review for rusfertide. rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (pv). the fda has set a prescription drug user fee act.
2026-02-19 12:00:00 Positive Phase 3 Data Demonstrate Potential For Entyvioยฎ (vedolizumab) To Address Treatment Gap For Children And Adolescents With Moderate To Severe Ulcerative Colitis
Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive data from the pivotal phase 3 kepler trial, which demonstrated that entyvioยฎ (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (uc), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 the results, presented at the 21st c.
2026-02-10 03:15:00 U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takedaโ€™s Oveporexton (tak-861) As A Potential First-in-class Therapy For Narcolepsy Type 1
Osaka, japan & cambridge, mass.--(business wire)--fda accepts new drug application and grants priority review for takedaโ€™s oveporexton as a potential first-in-class therapy for narcolepsy type 1.
2026-02-09 08:00:00 Iambic Announces Collaboration With Takeda To Advance Ai-driven Design Of Small Molecules
San diego & cambridge, mass.--(business wire)--iambic, a clinical-stage life science and technology company developing novel medicines using its ai-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with takeda that will use iambicโ€™s industry leading ai drug discovery models to advance a select set of high-priority small molecule programs, initially in takedaโ€™s oncology and gastrointestinal and inflammation therapeutic areas.
2026-01-29 01:37:00 VGFrZWRhIF JlcG9ydHMg VGhpcmQtcX VhcnRlciBG eTIwMjUgUm VzdWx0czog VXBkYXRlcy BGdWxsIFll YXIgT3V0bG 9vayBUbyBS ZWZsZWN0IF Z5dmFuc2XC riBHZW5lcm ljcyBJbXBh Y3QsIE9wZX ggRGlzY2lw bGluZSBBbm QgRnggVGFp bHdpbmQ7IF Byb2dyZXNz aW5nIFRvd2 FyZCBUaHJl ZSBUcmFuc2 Zvcm1hdGl2 ZSBMYXVuY2 hlcyBBaGVh ZA==
T3Nha2EsIG phcGFuLS0o YnVzaW5lc3 Mgd2lyZSkt LXRha2VkYS AodG9reW86 NDUwMi9ueX NlOnRhaykg dG9kYXkgYW 5ub3VuY2Vk IGVhcm5pbm dzIHJlc3Vs dHMgZm9yIH RoZSB0aGly ZCBxdWFydG VyIG9mIGZp c2NhbCB5ZW FyIDIwMjUg KG5pbmUgbW 9udGhzIGVu ZGVkIGRlY2 VtYmVyIDMx LCAyMDI1KS 4gdGhlIGdh cCBiZXR3ZW VuIGluY3Jl bWVudGFsIG dyb3d0aCAm IGxhdW5jaC Bwcm9kdWN0 cyByZXZlbn VlIGFuZCB2 eXZhbnNlIG Vyb3Npb24g aXMgbmFycm 93aW5nLCBh bmQgb3Blcm F0aW9uYWwg ZWZmaWNpZW 5jaWVzIGRy b3ZlIHllYX Itb24teWVh ciByZWR1Y3 Rpb25zIGlu IG9wZXJhdG luZyBleHBl bnNlcywgaW 5jbHVkaW5n IHImZC4gdG hlIGNvbXBh bnkgcmFpc2 VkIGl0cyBm dWxsLXllYX IgZm9yZWNh c3RzIGJhc2 VkIG9uIGNv c3QgZGlzY2 lwbGluZSBh bmQgZnggdG FpbHdpbmQs IHdoaWxlIG l0cyByZXZl bnVlIG1hbm FnZW1lbnQg Z3VpZGFuY2 UgaGEu
2026-01-05 07:00:00 VGFrZWRhIE FuZCBQcm90 YWdvbmlzdC BBbm5vdW5j ZSBTdWJtaX NzaW9uIE9m IE5ldyBEcn VnIEFwcGxp Y2F0aW9uIC huZGEpIEZv ciBSdXNmZX J0aWRlIEZv ciBUcmVhdG 1lbnQgT2Yg UG9seWN5dG hlbWlhIFZl cmEgKHB2KQ ==
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz LiAmIG5ld2 FyaywgY2Fs aWYuLS0oYn VzaW5lc3Mg d2lyZSktLX Rha2VkYSAo dHNlOjQ1MD IvbnlzZTp0 YWspIGFuZC Bwcm90YWdv bmlzdCB0aG VyYXBldXRp Y3MgKG5hc2 RhcTogcHRn eCkgKOKAnH Byb3RhZ29u aXN04oCdKS Bhbm5vdW5j ZWQgdGhlIH N1Ym1pc3Np b24gb2YgYS BuZXcgZHJ1 ZyBhcHBsaW NhdGlvbiAo bmRhKSB0by B0aGUgdS5z LiBmb29kIG FuZCBkcnVn IGFkbWluaX N0cmF0aW9u IChmZGEpIH NlZWtpbmcg YXBwcm92YW wgb2YgcnVz ZmVydGlkZS Bmb3IgdGhl IHRyZWF0bW VudCBvZiBh ZHVsdHMgd2 l0aCBwb2x5 Y3l0aGVtaW EgdmVyYSAo cHYpLiBydX NmZXJ0aWRl IGlzIGFuIG ludmVzdGln YXRpb25hbC BmaXJzdC1p bi1jbGFzcy BzdWJjdXRh bmVvdXNseS BhZG1pbmlz dGVyZWQgaG VwY2lkaW4g bWltZXRpYy BwZXB0aWRl IGRlc2lnbm VkIHRvIHJl Z3VsYXRlIG lyb24gaG9t ZW9zdGFzaX MgYW5kIHJl ZCBibG9vZC 4=
2025-12-18 03:00:00 VGFrZWRh4o CZcyBaYXNv Y2l0aW5pYi BMYW5kbWFy ayBQaGFzZS AzIFBsYXF1 ZSBQc29yaW FzaXMgRGF0 YSBTaG93IF Byb21pc2Ug VG8gRGVsaX ZlciBDbGVh ciBTa2luIE luIEEgT25j ZS1kYWlseS BQaWxsLCBD YXRhbHl6aW 5nIEEgTmV3 IEVyYSBPZi BUcmVhdG1l bnQ=
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGHigJlz IHphc29jaX RpbmliIGxh bmRtYXJrIH BoYXNlIDMg cGxhcXVlIH Bzb3JpYXNp cyBkYXRhIH Nob3cgcHJv bWlzZSB0by BkZWxpdmVy IGNsZWFyIH NraW4gaW4g YSBvbmNlLW RhaWx5IHBp bGwsIGNhdG FseXppbmcg YSBuZXcgZX JhIG9mIHRy ZWF0bWVudC 4=
2025-12-06 09:30:00 UHJvdGFnb2 5pc3QgQW5k IFRha2VkYS BQcmVzZW50 IExvbmdlci 10ZXJtIERh dGEgQXQgQX NoIDIwMjUg U2hvd2luZy BSdXNmZXJ0 aWRlIERlbG l2ZXJzIER1 cmFibGUgUm VzcG9uc2Ug QW5kIEhlbW F0b2NyaXQg Q29udHJvbC BJbiBQb2x5 Y3l0aGVtaW EgVmVyYQ==
TmV3YXJrLC BjYWxpZi4g JiBvc2FrYS wgamFwYW4g JiBjYW1icm lkZ2UsIG1h c3MuLS0oYn VzaW5lc3Mg d2lyZSktLX Byb3RhZ29u aXN0IHRoZX JhcGV1dGlj cywgaW5jLi Ao4oCccHJv dGFnb25pc3 TigJ0pIChu YXNkYXE6cH RneCkgYW5k IHRha2VkYS AodHNlOjQ1 MDIvbnlzZT p0YWspIGFu bm91bmNlIH RoYXQgbmV3 IDUyLXdlZW sgcmVzdWx0 cyBmcm9tIH RoZSBwaXZv dGFsIHBoYX NlIDMgdmVy aWZ5IHN0dW R5IGV2YWx1 YXRpbmcgcn VzZmVydGlk ZSBpbiBwYX RpZW50cyB3 aXRoIHBvbH ljeXRoZW1p YSB2ZXJhIC hwdikgd2ls bCBiZSBwcm VzZW50ZWQg aW4gYW4gb3 JhbCBwcmVz ZW50YXRpb2 4gYXQgdGhl IDY3dGggYW 1lcmljYW4g c29jaWV0eS BvZiBoZW1h dG9sb2d5IC hhc2gpIGFu bnVhbCBtZW V0aW5nIGFu ZCBleHBvc2 l0aW9uLiB0 aGVzZSBmaW 5kaW5ncyBm dXJ0aGVyIH JlaW5mb3Jj ZSBydXNmZX J0aWRl4oCZ cyBlZmZpY2 FjeSBhbmQg c2FmZXR5IG FuZCBkZW1v bnN0cmF0ZS BkdS4=
2025-11-19 06:30:00 QmVhY29uIE Jpb3NpZ25h bHMgQW5ub3 VuY2VzIE11 bHRpLXllYX IgRXhwYW5z aW9uIE9mIF N0cmF0ZWdp YyBDb2xsYW JvcmF0aW9u IFdpdGggVG FrZWRhIFRv IEFkdmFuY2 UgTmFyY29s ZXBzeSBEaW Fnbm9zaXMg QW5kIE5ldX JvYmlvbWFy a2VyIERpc2 NvdmVyeQ==
Qm9zdG9uLC Bub3YuIDE5 LCAyMDI1IC hnbG9iZSBu ZXdzd2lyZS kgLS0gYmVh Y29uIGJpb3 NpZ25hbHMs IGEgbGVhZG luZyBuZXVy b3RlY2hub2 xvZ3kgY29t cGFueSBwb3 dlcmluZyBh aS1kcml2ZW 4gbmV1cm9k aWFnbm9zdG ljcyBhbmQg cHJlY2lzaW 9uIG1lZGlj aW5lcyBmb3 IgdGhlIGJy YWluLCB0b2 RheSBhbm5v dW5jZWQgYS BtdWx0aS15 ZWFyIGV4cG Fuc2lvbiBv ZiBpdHMgc3 RyYXRlZ2lj IGNvbGxhYm 9yYXRpb24g d2l0aCB0YW tlZGEsIHdo aWNoIGJlZ2 FuIGluIDIw MjQuIHRoaX MgZXh0ZW5z aW9uIGxldm VyYWdlcyB0 aGUgYmVhY2 9uIHBsYXRm b3JtIHRvIG FjY2VsZXJh dGUgZGF0YS 1kcml2ZW4g ZGV2ZWxvcG 1lbnQgb2Yg c2xlZXAgYm lvbWFya2Vy cyBhbmQgcG F0dGVybnMs IGFuZCBzdX Bwb3J0cyBu ZXcgZGlhZ2 5vc3RpYyBw YXRod2F5cy B0aGF0IGNs b3NlIGxvbm dzdGFuZGlu ZyBjYXJlIG dhcHMgZm9y IHBlb3BsZS B3aXRoIG5h cmNvbGVwc3 kuIHVuZGVy IHRoZSB0ZX JtcyBvZiB0 aGUgYWdyZW VtZW50LCBi ZWFjb24gaX MgZWxpZ2li bGUgdG8gcm VjZWl2ZSB1 cCB0byAkMT A5IG1pbGxp b24gaW4gZG F0YSBsaWNl bnNlIGZlZX MgYW5kIHBv dGVudGlhbC BkZXZlbG9w bWVudCwgcm VndWxhdG9y eSwgYW5kIG NvbW1lcmNp YWwtYmFzZW QgbWlsZXN0 b25lcywgaW 5jbHVkaW5n IGVxdWl0eS BwYXJ0aWNp cGF0aW9uLg ==
2025-11-07 11:00:00 VGFrZWRhIF ByZXNlbnRz IE5ldyBEYX RhIFNob3dp bmcgTWV6YW dpdGFtYWIg KHRhay0wNz kpIFN1c3Rh aW5lZCBFZm ZlY3QgT24g S2lkbmV5IE Z1bmN0aW9u IDE4IE1vbn RocyBBZnRl ciBUcmVhdG 1lbnQgSW4g UHJpbWFyeS BJZ2EgTmVw aHJvcGF0aH k=
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRz ZTo0NTAyL2 55c2U6dGFr KSB0b2RheS Bhbm5vdW5j ZWQgbmV3IG ludGVyaW0g ZGF0YSBmcm 9tIHRoZSBw aGFzZSAxYi wgb3Blbi1s YWJlbCwgcH Jvb2Ytb2Yt Y29uY2VwdC BzdHVkeSBv ZiBzdWJjdX RhbmVvdXMg bWV6YWdpdG FtYWIgKHRh ay0wNzkpLC BhbiBhbnRp LWNkMzggbW 9ub2Nsb25h bCBhbnRpYm 9keSB3aXRo IGRpc2Vhc2 UtbW9kaWZ5 aW5nIHBvdG VudGlhbCwg aW4gcHJpbW FyeSBpbW11 bm9nbG9idW xpbiBhIChp Z2EpIG5lcG hyb3BhdGh5 LiBkYXRhIG Zyb20gdGhl IHN0dWR5IH Nob3dlZCB0 aGF0IGtpZG 5leSBmdW5j dGlvbiAoZW dmcikgcmVt YWluZWQgc3 RhYmxlIGlu IHBhdGllbn RzIHdpdGgg aWdhIG5lcG hyb3BhdGh5 IHRocm91Z2 ggd2VlayA5 NiDigJMgdX AgdG8gMTgg bW9udGhzIG FmdGVyIHRo ZSBsYXN0IG 1lemFnaXRh bWFiIGRvc2 UuMSB0aGUg cmVzdWx0Lg ==
2025-10-30 03:04:00 VGFrZWRhIF JlcG9ydHMg Rmlyc3QgSG FsZiBGeTIw MjUgUmVzdW x0cywgV2l0 aCBCdXNpbm VzcyBGdW5k YW1lbnRhbH MgVHJhY2tp bmcgQXMgUG xhbm5lZC4g VXBkYXRlcy BGdWxsIFll YXIgT3V0bG 9vayBUbyBS ZWZsZWN0IE Z4IEltcGFj dCBBbmQgUG lwZWxpbmUg SW1wYWlybW VudC4=
T3Nha2EsIG phcGFuLS0o YnVzaW5lc3 Mgd2lyZSkt LXRha2VkYS AodG9reW86 NDUwMi9ueX NlOnRhaykg dG9kYXkgYW 5ub3VuY2Vk IGVhcm5pbm dzIHJlc3Vs dHMgZm9yIH RoZSBmaXJz dCBoYWxmIG 9mIGZpc2Nh bCB5ZWFyID IwMjUgKHNp eCBtb250aH MgZW5kZWQg c2VwIDMwLC AyMDI1KSBh bmQgdXBkYX RlZCBpdHMg ZnVsbC15ZW FyIG91dGxv b2suIHRha2 VkYSBjaGll ZiBleGVjdX RpdmUgb2Zm aWNlciwgY2 hyaXN0b3Bo ZSB3ZWJlci wgY29tbWVu dGVkOiDigJ x0YWtlZGHi gJlzIGZpc2 NhbCB5ZWFy IDIwMjUgZm lyc3QgaGFs ZiByZXN1bH RzIGFyZSBj b25zaXN0ZW 50IHdpdGgg b3VyIGV4cG VjdGF0aW9u cyBmb3IgY2 9yZSBidXNp bmVzcyBwcm 9ncmVzcyBp biB0aGlzIH llYXIgb2Yg dHJhbnNpdG lvbiB0byBh IG5ldyBwaG FzZSBmb2N1 c2luZyBvbi BuZXcgcHJv ZHVjdCBsYX VuY2hlcy4g b3VyIHVwZG F0ZWQgZnVs bC15ZWFyIG 91dGxvb2sg cmVmbGVjdH MgaW1wYWly bWVudCBjaG Eu
2025-10-21 20:25:00 VGFrZWRhIE VudGVycyBH bG9iYWwgU3 RyYXRlZ2lj IFBhcnRuZX JzaGlwIFdp dGggSW5ub3 ZlbnQgQmlv bG9naWNzIF RvIEJvbHN0 ZXIgT25jb2 xvZ3kgUGlw ZWxpbmUgV2 l0aCBOZXh0 LWdlbmVyYX Rpb24gSW52 ZXN0aWdhdG lvbmFsIE1l ZGljaW5lcy BGb3IgVHJl YXRtZW50IE 9mIFNvbGlk IFR1bW9ycw ==
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRz ZTo0NTAyL2 55c2U6dGFr KSB0b2RheS Bhbm5vdW5j ZWQgdGhhdC BpdCBoYXMg ZW50ZXJlZC BpbnRvIGEg bGljZW5zZS BhbmQgY29s bGFib3JhdG lvbiBhZ3Jl ZW1lbnQgd2 l0aCBpbm5v dmVudCBiaW 9sb2dpY3Mg KGhrZXg6ID AxODAxKSBm b3IgdGhlIG RldmVsb3Bt ZW50LCBtYW 51ZmFjdHVy aW5nIGFuZC Bjb21tZXJj aWFsaXphdG lvbiBvZiB0 d28gbGF0ZS 1zdGFnZSBv bmNvbG9neS BtZWRpY2lu ZXMsIGliaT M2MyBhbmQg aWJpMzQzLC B3b3JsZHdp ZGUgb3V0c2 lkZSBvZiBn cmVhdGVyIG NoaW5hLiog aWJpMzYzIG lzIGJlaW5n IGV2YWx1YX RlZCBpbiBu b24tc21hbG wgY2VsbCBs dW5nIGFuZC Bjb2xvcmVj dGFsIGNhbm NlcnMgYW5k IGhhcyBzaG 93biBwb3Rl bnRpYWwgZW ZmaWNhY3kg aW4gYWRkaX Rpb25hbCBz b2xpZCB0dW 1vciB0eXBl cy4gaWJpMz QzIGlzIGJl aW5nLg==
2025-10-14 05:00:00 TmFibGEgQm lvIFNpZ25z IFNlY29uZC BUYWtlZGEg Q29sbGFib3 JhdGlvbiBU byBBZHZhbm NlIEFpLWRy aXZlbiBEZX NpZ24gT2Yg UHJvdGVpbi BUaGVyYXBl dXRpY3M=
Q2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS1uYW JsYSBiaW8s IGEgYmlvdG VjaG5vbG9n eSBjb21wYW 55IHBpb25l ZXJpbmcgZG Ugbm92byB0 aGVyYXBldX RpY3MgZGVz aWduIHdpdG ggZ2VuZXJh dGl2ZSBhaS wgdG9kYXkg YW5ub3VuY2 VkIGEgbmV3 LCBtdWx0aS 15ZWFyIHJl c2VhcmNoIG NvbGxhYm9y YXRpb24gd2 l0aCB0YWtl ZGEuIHVuZG VyIHRoZSB0 ZXJtcyBvZi B0aGUgYWdy ZWVtZW50LC BuYWJsYSBi aW8gd2lsbC ByZWNlaXZl IGRvdWJsZS 1kaWdpdCBt aWxsaW9ucy BpbiB1cGZy b250IGFuZC ByZXNlYXJj aCBjb3N0IH BheW1lbnRz IGFuZCBpcy BlbGlnaWJs ZSB0byByZW NlaXZlIHN1 Y2Nlc3MtYm FzZWQgcGF5 bWVudHMgdG hhdCBtYXkg ZXhjZWVkIC QxIGJpbGxp b24gaW4gdG 90YWwuIHRo aXMgc2Vjb2 5kIGNvbGxh Ym9yYXRpb2 4gd2lsbCBk ZXBsb3kgbm FibGEgYmlv 4oCZcyBwcm 9wcmlldGFy eSBiaW9tb2 xlY3VsYXIg ZGVzaWduIH BsYXRmb3Jt LCBqb2luLg ==
2025-09-23 18:04:00 MjAsMDAwIC sgVGFrZWRh IEVtcGxveW VlcyBWb3Rl ZCBUbyBTZW xlY3QgRm91 ciBOZXcgR2 xvYmFsIENv cnBvcmF0ZS BTb2NpYWwg UmVzcG9uc2 liaWxpdHkg Q29sbGFib3 JhdGlvbnMg VG8gQWR2YW 5jZSBDbGlt YXRlLXJlc2 lsaWVudCBI ZWFsdGggU3 lzdGVtcyBJ biA5NCBDb3 VudHJpZXM=
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRv a3lvOjQ1MD IvbnlzZTog dGFrKSB0b2 RheSBjb21t aXR0ZWQgan B5IDQuNiBi aWxsaW9uIC hhcHByb3gu IHVzZCAzMi 4xIG1pbGxp b24pIHRvIG ZvdXIgbmV3 IGdsb2JhbC Bjb3Jwb3Jh dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5IChjc3Ip IHBhcnRuZX JzIGFzIHBh cnQgb2YgdG hlIGNvbXBh bnnigJlzIG 9uZ29pbmcg Y29tbWl0bW VudCB0byBi dWlsZGluZy BjbGltYXRl LXJlc2lsaW VudCBoZWFs dGggc3lzdG VtcyBpbiBs b3ctIGFuZC BtaWRkbGUt aW5jb21lIG NvdW50cmll cyBhcm91bm QgdGhlIHdv cmxkLiBhbW lkIHJpc2lu ZyB0ZW1wZX JhdHVyZXMg YW5kIGV4dH JlbWUgd2Vh dGhlciBldm VudHMsIHRh a2VkYSByZW NvZ25pemVz IGFuIHVyZ2 VudCBuZWVk IHRvIGVuc3 VyZSB0aGF0 IGhlYWx0aG NhcmUgcmVt YWlucyByZX NpbGllbnQg YW5kIGFjY2 Vzc2libGUs IHBhcnRpLg ==
Takeda Pharmaceutical

๐Ÿ“ฐ Browse additional press releases for Takeda Pharmaceutical!

Sign up for free or log in

๐Ÿ”“ Unlock our free guide: "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks"

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal